Abstract:Introduction: CXCL17 is a mucosally secreted protein, and the most recently identified human chemokine, an assignment based on protein fold prediction and chemotactic activity for leukocytes. However, these credentials have been the subject of much recent discussion and no experimental evidence has been presented regarding the definitive structure of CXCL17. In this study, we evaluated the structural and chemoattractant credentials of CXCL17 to better characterize this molecule, and gain deeper insights into its functional role as a glycosaminoglycan (GAG) binding protein. Methods: In the absence of structural information, in silico modeling techniques assessed the likelihood of CXCL17 adopting a chemokine fold. Recombinant CXCL17 was synthesized in mammalian and prokaryotic systems. Modified Boyden chamber and real-time chemotaxis assays assessed the ability of CXCL17 to promote chemotaxis of murine splenocytes, human neutrophils, and CXCR1 transfectants. The efficacy of CXCL17 binding to GAGs was quantified with solid-phase assays and bio-layer interferometry techniques. Results: All modeling efforts failed to support classification of CXCL17 as a chemokine based on its predicted conformation. Recombinant CXCL17 was observed to dimerize as a function of concentration, a characteristic of several chemokines. Contrary to a previous report, CXCL17 was not chemotactic for murine splenocytes, although it was a low-potency chemoattractant for human neutrophils at micromolar concentrations, several orders of magnitude higher than those required for CXCL8. As anticipated owing to its highly basic nature, CXCL17 bound to GAGs robustly, with key C-terminal motifs implicated in this process. While inactive via CXCR1, CXCL17 was found to inhibit CXCR1-mediated chemotaxis of transfectants to CXCL8 in a dose-dependent manner. Discussion: In summary, despite finding little evidence for chemokine-like structure and function, CXCL17 readily bound GAGs, and could modulate chemotactic responses to another chemokine in vitro. We postulate that such modulation is a consequence of superior GAG binding, and that C-terminal fragments of CXCL17 may serve as prototypic inhibitors of chemokine function.

Mucosal Chemokine CXCL17: What is Known and Not Known

What defines a chemokine? - The curious case of CXCL17

Human Monocyte-Derived Dendritic Cells Expressing Both Chemotactic Cytokines IL-8, MCP-1, RANTES and Their Receptors, and Their Selective Migration to These Chemokines.

A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation

CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling

CXCL17 is a proinflammatory chemokine and promotes neutrophil trafficking

The cryptic role of CXCL17/CXCR8 axis in the pathogenesis of cancers: a review of the latest evidence

CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans

Role of CX3CL1 in Diseases

A CXCL ortholog from Hippocampus abdominalis: Molecular features and functional delineation as a pro-inflammatory chemokine

Role of chemokine receptors in gastrointestinal mucosa

The Role and Clinical Significance of the CXCL17-CXCR8 (GPR35) Axis in Breast Cancer

The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment

CXCL13: a common target for immune-mediated inflammatory diseases

CXCL17 Is Dispensable during Hypervirulent Mycobacterium tuberculosis HN878 Infection in Mice

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems

IL-17C in human mucosal immunity: More than just a middle child

Advances in animal mucosal immune and cytokines

Monocyte Chemoattractant Protein-1 (MCP-1): An Overview

Chemokines in immunity

Biophysical characterization of the CXC chemokine receptor 2 ligands